# Oliver Sexton

> Oliver Sexton is a seed investor at Midven (London) backing Biotechnology and Health Care. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Midven](https://shizune.co/investors/profile/midven)
- Location: London, United Kingdom
- Total investments: 17
- Last investment: Jul 2026
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/oliver-sexton/8/b29/278

Oliver Sexton is a seed investor at Midven in London focused on Biotechnology and Health Care. Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 65% |
| Health Care | 4 | 24% |
| Medical | 3 | 18% |
| AgTech | 2 | 12% |
| Life Science | 2 | 12% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 8 | 47% |
| Pre-Seed | 3 | 18% |
| Series A | 2 | 12% |
| Venture - Series Unknown | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Revolver Therapeutics | Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K | Pre-Seed | Jul 03, 2026 |  |
| QuberTech | QuberTech develops biotechnology solutions to create an alternative natural rubber supply chain. The company engineers dandelion crops using precision breeding and gene editing to increase latex production in their roots to commercially viable levels. It integrates these crop innovations with soil-free, controlled-environment aeroponic farmingsystems designed for industrial rubber production. QuberTech focuses on controlled indoor cultivation to reduce exposure to climate and disease risks associated with traditional plantations. Its technology targets early applications in sectors that use high-specification natural rubber, including medical products, footwear, and fashion. The company also participates in collaborative research and development programmes such as the QuBOOSTR consortium to advance its platform toward commercial-scale facilities. | $4.6M | Seed | May 20, 2026 |  |
| Resurrect Bio | Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $10.3M | Series A | Feb 17, 2026 |  |
| Solasta Bio | Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection. | $14M | Series A | Sep 11, 2024 |  |
| MitoRx Therapeutics | MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. | $5M | Seed | Dec 13, 2023 |  |
| twig bio | twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients. | $3.7M | Pre-Seed | Sep 10, 2023 |  |
| Resurrect Bio | Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $2M | Seed | May 16, 2023 |  |
| Solasta Bio | Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection. | $4.9M | Seed | Mar 27, 2023 |  |
| Solasta Bio | Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection. | $4.9M | Seed | Mar 27, 2023 |  |
| MicrofluidX | MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. | $4.3M | Seed | Dec 08, 2022 |  |

10 of 17 investments shown.

## Co-investors
- [Future Planet Capital](https://shizune.co/investors/profile/future-planet-capital) — VC Fund, 7 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 6 deals together
- [SIS Ventures](https://shizune.co/investors/profile/sis-ventures) — VC Fund, 4 deals together
- [Cavallo Ventures](https://shizune.co/investors/profile/cavallo-ventures) — VC Fund, 3 deals together
- [Rubio Impact Ventures](https://shizune.co/investors/profile/rubio-impact-ventures-nl) — VC Fund, 3 deals together
- [The Yield Lab Europe](https://shizune.co/investors/profile/the-yield-lab-europe) — VC Fund, 3 deals together

## About Midven

VC Fund · Birmingham, United Kingdom

Midven is a specialist venture capital company providing investment to fast growing small and medium sized enterprises ("SMEs"), run by an energetic, experienced and hands-on team of investment managers.

5 contacts available at Midven.

| Name | Title | Profile |
| --- | --- | --- |
| Roger Wood | Director/Shareholder | https://shizune.co/investors/profile/roger-wood-2 |
| Aanisah Begg | Investment Manager | https://shizune.co/investors/profile/aanisah-begg |
| Alexander Leigh | Investment Committee Member | https://shizune.co/investors/profile/alexander-leigh |
| Andrew Muir | Investment Director | https://shizune.co/investors/profile/andrew-muir |
| Giovanni Finocchio | Investment Manager | https://shizune.co/investors/profile/giovanni-finocchio |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in United Kingdom](https://shizune.co/investors/biotech-angel-investors-united-kingdom)
- [Biotechnology Angel Investors in United Kingdom](https://shizune.co/investors/biotechnology-angel-investors-united-kingdom)

## FAQ

### What does Oliver Sexton invest in?

Oliver Sexton invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 17 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Oliver Sexton last invest?

The most recent investment recorded for Oliver Sexton closed in Jul 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co